Hematologic responses to bortezomib by cohort and overall
| Response . | Once-weekly bortezomib, cohort no.: dose (n) . | Twice-weekly bortezomib, cohort no.: dose (n) . | Total, N = 30 (%) . | |||||
|---|---|---|---|---|---|---|---|---|
| 1: 0.7 mg/m2 (n = 3) . | 2: 1.0 mg/m2 (n = 3) . | 3: 1.3 mg/m2 (n = 3) . | 4: 1.6 mg/m2,(n = 5*) . | 5: 0.7 mg/m2 (n = 3) . | 6: 1.0 mg/m2 (n = 6) . | 7: 1.3 mg/m2 (n = 7) . | ||
| Complete response | — | — | — | 3 | — | 1 | 2 | 6 (20) |
| Partial response | — | 1 | 3 | 1 | — | 2 | 2 | 9 (30) |
| Stable disease | 3 | 2 | — | 1 | 3 | 3 | 2 | 14 (47) |
| Progressive disease | — | — | — | — | — | — | 1 | 1 (3) |
| Response . | Once-weekly bortezomib, cohort no.: dose (n) . | Twice-weekly bortezomib, cohort no.: dose (n) . | Total, N = 30 (%) . | |||||
|---|---|---|---|---|---|---|---|---|
| 1: 0.7 mg/m2 (n = 3) . | 2: 1.0 mg/m2 (n = 3) . | 3: 1.3 mg/m2 (n = 3) . | 4: 1.6 mg/m2,(n = 5*) . | 5: 0.7 mg/m2 (n = 3) . | 6: 1.0 mg/m2 (n = 6) . | 7: 1.3 mg/m2 (n = 7) . | ||
| Complete response | — | — | — | 3 | — | 1 | 2 | 6 (20) |
| Partial response | — | 1 | 3 | 1 | — | 2 | 2 | 9 (30) |
| Stable disease | 3 | 2 | — | 1 | 3 | 3 | 2 | 14 (47) |
| Progressive disease | — | — | — | — | — | — | 1 | 1 (3) |
One patient was not evaluable for response.